CAR-T cells take on stubborn muscle disease in first human test
NCT ID NCT07086404
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new treatment called GC012F, which uses a patient's own immune cells (CAR-T cells) to target and attack the cause of idiopathic inflammatory myopathy, a group of rare muscle diseases. The study will enroll 12 adults whose disease has not responded to standard therapies. The main goal is to check safety, including side effects, and to see how long the modified cells last in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GC012F CAR-T cells
What this could lead to
If successful, this could point toward a new treatment option for people with hard-to-treat inflammatory muscle disease.
What could go wrong
This is a very early, small trial (12 people) focused on safety, not effectiveness. CAR-T therapy can cause serious side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC INFLAMMATORY MYOPATHY (IIM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital of Tongji Medical Colledge, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
Contact